Media & Events » In the News » FDA approves Teva's Jerusalem facility

FDA approves Teva's Jerusalem facility

Sep. 13, 2011
Source: Globes

The US Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries Ltd's (Nasdaq: TEVA; TASE: TEVA) Oral Solid Dosage (OSD) manufacturing facility in Jerusalem.Teva has received a closeout letter from the US Food and Drug Administration (FDA) stating that the company has addressed the issues raised by the FDA in a warning letter in January.

In the January inspection of the facility, the FDA raised questions about its current Good Manufacturing Practices (cGMP). The FDA found no adverse finding in a new inspection of the facility in June.

Teva's share price fell 1.5% on Nasdaq yesterday to $37.92, giving a market cap of $33.8 billion, and rose 0.6% at the opening on the TASE today to NIS 140. 

News Archive

Did You Know?

  • The Hebrew University ranks 12th worldwide in biotechnology patents.
     
  • $2 billion in annual sales are generated from two life science products originating from scientific innovation at the Hebrew University of Jerusalem. These include Exelon (marketed by Novartis) for the treatment of Alzheimer’s disease and Doxil (marketed by J&J) for the treatment of cancer..